Raxibacumab

(Raxibacumab®)

Raxibacumab

Latest News

loading GIF

Drug updated on 4/17/2024

Dosage FormInjection (intravenous; 1700 mg/34 mL [50 mg/mL])
Drug ClassMonoclonal antibody against B. anthracis
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult and pediatric patients with inhalational anthrax due to bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Raxibacumab is indicated for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis in both adult and pediatric patients, used in combination with appropriate antibacterial drugs. It is also an alternative when other therapies are not available or suitable.
  • The study focused on FDA-approved anthrax antitoxins, including Raxibacumab, in a systematic review/meta-analysis context.
  • All three FDA-approved anthrax antitoxins, including Raxibacumab, demonstrated significant improvement in survival as monotherapy over placebo in preclinical models involving rabbits and non-human primates.
  • There was no significant improvement found when combining an antitoxin like Raxibacumab with antimicrobial therapy compared to using antimicrobial therapy alone. This suggests that while useful under certain circumstances, the role of such antitoxins should be carefully considered alongside traditional treatments.
  • Case studies of 25 patients treated with these types of antitoxins for systemic anthrax disease were reported; 17 survived. However, due to the small sample size and lack of a control group, it is difficult to directly compare the effectiveness among different options, including Raxibacumab.
  • For post-exposure prophylaxis (PEP), animal studies indicated that monotherapy using any one among the approved antitoxins significantly improved survival rates over placebo, especially if administered early after exposure.

Product Monograph / Prescribing Information

Document TitleYearSource
Raxibacumab Prescribing Information.2021Emergent BioSolutions Inc., Gaithersburg, MD

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines